Current vaccine strains show high neutralization against the latest variants, but the LP.8.1 antigen may provide similar or moderately higher cross-reactive antibody response.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
None of the specified outcomes in 6.2 million vaccine recipients met the criteria for a safety signal.
Also, Africa is struggling to meet its end-of-September vaccination coverage goal of 10%.
The state has stepped into oxygen negotiations, created resource depots, and taken other actions.
COVID-19 vaccine effectiveness (VE) against the Delta (B1617.2) variant was 65% in those fully vaccinated, according to a population-based study in Norway. The results, published in Eurosurveillance yesterday, looked at 4,204,859 infected adults without previous COVID-19 from mid-April to mid-August.
After years of decline, US hospitals saw significant increases in HAIs.
The odds of long COVID-19 fall by more than half after two doses of vaccine.
The ECDC says a third dose should already be considered in the immune-compromised.
"A transparent, thorough, and objective review of the data by the FDA is critical."
The rheumatoid arthritis drug baricitinib was shown to reduce mortality in hospitalized COVID-19 patients, according to a randomized, controlled trial published in The Lancet Respiratory Medicine yesterday. Baricitinib acts as a Janus kinases inhibitor and is under emergency use authorization to treat severe COVID-19 by the US Food and Drug Administration.
Even those who had mild COVID-19 are at increased risk for major declines in kidney function.
